Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)

NCT03461952 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

NETWORK

Sponsor class

Stopped cfDNA screening data found that the prevalence of POLE/POLD1 mutations was lower than expected. It was determined that there are no feasible options to amend this study in a fashion that would not be duplicative of other currently accruing trials.

Conditions

Advanced Solid Tumors

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]
[object Object]